Cargando…

Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases

IMPORTANCE: Understanding RAS dependency and mechanisms of RAS activation in non-V600 BRAF variant cancers has important clinical implications. This is the first study to date to systematically assess RAS dependency of BRAF alterations with real-world cancer genomic databases. OBJECTIVE: To evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yiqing, Yu, Hanzhong, Ida, Cris M., Halling, Kevin C., Kipp, Benjamin R., Geiersbach, Katherine, Rumilla, Kandelaria M., Gupta, Sounak, Lin, Ming-Tseh, Zheng, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844594/ https://www.ncbi.nlm.nih.gov/pubmed/33507258 http://dx.doi.org/10.1001/jamanetworkopen.2020.35479

Ejemplares similares

BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)
por: Slostad, Jessica A., et al.
Publicado: (2021)

Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy
por: Blessing, Melissa M., et al.
Publicado: (2018)

Impact of RNA degradation on fusion detection by RNA-seq
por: Davila, Jaime I., et al.
Publicado: (2016)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Discovery of nonautonomous modulators of activated Ras
por: Corchado-Sonera, Marcos, et al.
Publicado: (2022)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

Mitonuclear Epistasis for Development Time and Its Modification by Diet in Drosophila
por: Mossman, Jim A., et al.
Publicado: (2016)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia
por: Gupta, Sounak, et al.
Publicado: (2021)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
por: Zheng, Gang, et al.
Publicado: (2015)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
por: Lokhandwala, Parvez M., et al.
Publicado: (2019)

Ras/MAPK Modifier Loci Revealed by eQTL in Caenorhabditis elegans
por: Sterken, Mark G., et al.
Publicado: (2017)

Lysines K117 and K147 play conserved roles in Ras activation from Drosophila to mammals
por: Singh, Jiya, et al.
Publicado: (2023)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells
por: Arozarena, Imanol, et al.
Publicado: (2014)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding
por: Martinez Fiesco, Juliana A., et al.
Publicado: (2022)

Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
por: Trebino, Tarah, et al.
Publicado: (2023)

Conidial Morphogenesis and Septin-Mediated Plant Infection Require Smo1, a Ras GTPase-Activating Protein in Magnaporthe oryzae
por: Kershaw, Michael J., et al.
Publicado: (2019)

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
por: Bonaldi, Elisa, et al.
Publicado: (2021)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
por: Lim, Jinsun, et al.
Publicado: (2023)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis
por: Mincu, Raluca I., et al.
Publicado: (2019)

Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
por: Patel, Kishan K., et al.
Publicado: (2021)

BRAF Alteration in Central and Peripheral Nervous System Tumors
por: Srinivasa, Komal, et al.
Publicado: (2020)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation
por: Kikuchi, Yasuko, et al.
Publicado: (2013)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
por: Shetty, Omshree, et al.
Publicado: (2022)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma
por: Xin, Hao-Yang, et al.
Publicado: (2023)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
por: Oikonomou, Eftychia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rp01mh4t54k2qb5gdbkq7cm2v8